Insulin Resistance in Women Over 40: Symptoms and What to Test
Insulin resistance in women over 40: the signs standard bloods miss.
By the time fasting glucose drifts up, insulin has usually been compensating for years. Here’s what changes after 40, the symptoms women notice first, and the markers that show it early.
Insulin resistance is when your cells respond less readily to insulin, so the pancreas releases more of it to keep blood sugar in range. In women it tends to accelerate from the early 40s, as falling oestrogen reduces insulin sensitivity in muscle, liver and fat and shifts body fat toward the abdomen. Blood sugar can read “normal” for years while insulin quietly rises to hold it there.
That is why the earliest signs are rarely high glucose. They are afternoon energy crashes, weight settling around the middle, brain fog, sugar cravings and broken sleep. A standard blood panel measures glucose and HbA1c, not insulin, so the pattern often stays invisible until it is advanced. Fasting insulin, HOMA-IR and the triglyceride-to-HDL ratio reveal it far earlier.
Insulin resistance can be present for years while fasting glucose and HbA1c still read normal.
From the early 40s, falling oestrogen reduces insulin sensitivity and moves body fat to the abdomen. The shift tracks ovarian ageing, not age alone.
The symptoms women notice first are energy crashes, central weight gain, brain fog, sugar cravings and disrupted sleep, not high blood sugar.
A normal body weight does not rule it out. Visceral and liver fat matter more than the number on the scale.
Fasting insulin, HOMA-IR and the triglyceride-to-HDL ratio detect insulin resistance earlier than glucose or HbA1c.
Why 40 is the turning point.
Oestrogen does quiet metabolic work. It helps muscle, liver and fat tissue respond to insulin, supports a healthier pattern of fat storage, and helps the pancreas regulate how much insulin it releases.1 As oestrogen falls through the late 30s and 40s, that support is gradually withdrawn. Insulin sensitivity drops, and fat begins to move from the hips and thighs toward the abdomen.
This is not simply ageing. Longitudinal data show the change tracks ovarian ageing, the menopausal transition itself, rather than chronological age.2 Across the transition, visceral fat (the metabolically active fat around the organs) rises and independently predicts metabolic syndrome, type 2 diabetes and cardiovascular disease in women.3 Midlife weight gain around the middle directly favours insulin resistance.4
Most women blame willpower. The real driver is a measurable shift in how the body handles insulin and fat.
The symptoms women notice first.
Insulin resistance rarely announces itself as high blood sugar. It shows up as the day-to-day pattern women describe most often: a heavy energy crash an hour or two after eating, strong afternoon cravings for sugar or carbohydrates, and weight that settles around the middle and stops responding to the food and exercise that used to work.
Brain fog, low mood and patchy concentration tend to travel with it, and so does broken sleep. The relationship runs both ways. Poor sleep quality is itself associated with greater insulin resistance in women after menopause, so disrupted nights can deepen a metabolic pattern that is already forming.5 Because these symptoms overlap with perimenopause and with simply being busy, they are easy to put down to stress and leave unexamined.
Why a standard panel misses it.
When insulin sensitivity falls, the pancreas compensates by making more insulin. For years that compensation works, and blood sugar stays normal. In the Whitehall II cohort, insulin sensitivity declined steeply in the five years before a diabetes diagnosis, while fasting and post-load glucose only climbed sharply in the final three.6 Glucose is a late signal. Insulin moves first.
Body weight can mislead in the same way. Lean and normal-weight women can be profoundly insulin resistant, carrying excess visceral and liver fat with normal fasting glucose and normal HbA1c while post-meal insulin runs high.7 This “metabolically obese, normal-weight” pattern is well described, and a healthy BMI does not rule it out.8 A standard panel measures glucose and HbA1c. Neither shows what insulin is doing.
The markers that catch it early.
Performance biology measures insulin directly, not only the glucose it controls. These markers can flag insulin resistance while it is still early and modifiable. Thresholds vary between laboratories and should be read with clinical context.910
| Marker | Early signal | Why a standard panel misses it |
|---|---|---|
| Fasting insulin | Rising | Not on a routine panel; only glucose is measured |
| HOMA-IR | Above optimal | Needs fasting insulin, which is rarely ordered |
| Triglyceride : HDL | Elevated | Lipids can read normal while the ratio flags resistance |
| 2-hour insulin (OGTT) | Exaggerated | Glucose tolerance can pass while insulin spikes |
| HbA1c | Moves late | Rises only once blood sugar is already high |
| Fasting glucose | Moves last | Stays normal until resistance is advanced |
Insulin, usually, is not →
Which is why the pattern can stay hidden on a routine blood test for years.
What the data actually says.
Insulin resistance is one of the earliest measurable metabolic changes in women over 40, often present years before blood sugar rises.
Falling oestrogen, not age alone, drives the shift toward central fat and lower insulin sensitivity.
The first symptoms are energy, weight, mood and sleep, not thirst or high blood sugar.
A normal weight does not rule out insulin resistance; visceral and liver fat are the real drivers.
Fasting insulin, HOMA-IR and the triglyceride-to-HDL ratio detect the pattern earlier than glucose or HbA1c.
Frequently asked.
What are the symptoms of insulin resistance in women over 40?
The common early signs are energy crashes after meals, weight gain around the middle, sugar or carbohydrate cravings, brain fog and disrupted sleep. Classic blood-sugar symptoms like thirst and frequent urination usually appear much later, if at all.
Can you have insulin resistance with normal blood sugar?
Yes. The pancreas can compensate for years by producing more insulin, which keeps fasting glucose and HbA1c in the normal range while insulin runs high. Fasting insulin and HOMA-IR reveal the pattern far earlier than glucose does.
What tests detect insulin resistance early?
Fasting insulin, HOMA-IR (calculated from fasting glucose and insulin), the triglyceride-to-HDL ratio, and a glucose tolerance test with insulin measured alongside glucose. A standard panel measures glucose and HbA1c, which change late.
Does menopause cause insulin resistance?
The menopausal transition accelerates it. Falling oestrogen lowers insulin sensitivity and shifts fat toward the abdomen, a change linked to ovarian ageing rather than chronological age alone.
Your metabolism, measured.
A structured six-month protocol built on a complete metabolic and hormonal picture, then measured again as it changes.
Apply to the programReferences.
- Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–338. doi.org/10.1210/er.2012-1055
- El Khoudary SR, Nasr A. Cardiovascular Disease in Women: Does Menopause Matter? Curr Opin Endocr Metab Res. 2022;27:100419. doi.org/10.1016/j.coemr.2022.100419
- Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women’s Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring). 2010;18(3):604–610. doi.org/10.1038/oby.2009.251
- Chedraui P, Pérez-López FR. Metabolic syndrome during female midlife: what are the risks? Climacteric. 2019;22(2):127–132. doi.org/10.1080/13697137.2018.1561666
- Kline CE, Hall MH, Buysse DJ, Earnest CP, Church TS. Poor sleep quality is associated with insulin resistance in postmenopausal women with and without metabolic syndrome. Metab Syndr Relat Disord. 2018;16(4):183–189. doi.org/10.1089/met.2018.0013
- Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215–2221. doi.org/10.1016/S0140-6736(09)60619-X
- Ding C, Chan Z, Chooi YC, et al. Regulation of glucose metabolism in nondiabetic, metabolically obese normal-weight Asians. Am J Physiol Endocrinol Metab. 2018;314(5):E494–E502. doi.org/10.1152/ajpendo.00382.2017
- Ding C, Chan Z, Magkos F. Lean, but not healthy: the ‘metabolically obese, normal-weight’ phenotype. Curr Opin Clin Nutr Metab Care. 2016;19(6):408–417. doi.org/10.1097/MCO.0000000000000317
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi.org/10.1007/BF00280883
- Pantoja-Torres B, Toro-Huamanchumo CJ, Urrunaga-Pastor D, et al. High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults. Diabetes Metab Syndr. 2019;13(1):382–388. doi.org/10.1016/j.dsx.2018.10.006
